MARKETS
Earnings

CORRECTION: Purple Biotech Q2 EPS $(0.41) Beats $(0.98) Estimate

Aug 7, 2026 · 09:24 AM ET· updated 44m ago

Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.98) by 58.16 percent. This is a 89.75 percent increase over losses of $(4.00) per share from

Share
Why It Matters

Purple Biotech lost less money per share than experts thought it would—which is good news for a company still losing money overall. When a struggling company does better than expected, it shows they're making progress, so watch if they keep improving or start making money.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.